Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings

Opioid agonist treatment is effective but resource intensive to administer safely in custodial settings, leading to significant under-treatment of opioid dependence in these settings world-wide. This study assessed the safety of subcutaneous slow-release depot buprenorphine in custody.Open-label, non-randomized trial.Correctional centres in New South Wales, Australia.Sixty-seven men and women, aged ≥ 18 years of various security classifications...